Biomedical Engineering Reference
In-Depth Information
polymerized hemoglobin when red cells might be unavailable. J. Amer. Coll.
Surgeons 2002; 195: 445±452.
14. Gould, SA, Sehgal LR, Sehgal HL, DeWoskin R, Moss GS: The clinical
development of human polymerized hemoglobin, in Blood Substitutes: Principles,
Methods, Products and Clinical Trials. Vol. 2 (Chang TMS, ed.) Karger: Basel,
1998, pp. 12±28.
15. Sprung J, Kindscher JD, Wahr JA, Levy JH, Monk TG, Moritz MW, O'Hara PJ: The
use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a
multicenter, randomized, single-blinded trial. Anesth. Analg. 2002; 94: 799±808.
16. Pearce LB, Gawryl MS: Overview of preclinical and clinical efficacy of Biopure's
HBOCs; in Blood Substitutes: Principles, Methods, Products and Clinical Trials.
Vol. 2 (Chang TMS, ed.) Karger: Basel, 1998, pp. 82±98.
17. D'Agnillo F, Chang TMS: Polyhemoglobin-superoxide dismutase, catalase as a
blood substitute with antioxidant properties. Nature Biotechnol. 1998; 16(7): 667±
671.
18. D'Agnillo F, Chang TMS: Absence of hemoprotein-associated free radical events
following oxidant challenge of crosslinked hemoglobin-superoxide dismutase-
catalase. Free Radical Biol. Med. 1998; 24(6): 906±912.
19. Razack S, D'Agnillo F, Chang TMS: Effects of polyhemoglobin±catalase±
superoxide dismutase on oxygen radicals in an ischemia-reperfusion rat intestinal
model. Artif. Cells, Blood Substit. Immobiliz. Biotechnol. 1997; 25: 181±192.
20. Powanda D, Chang TMS: Cross-linked polyhemoglobin±superoxide dismutase±
catalase supplies oxygen without causing blood brain barrier disruption or brain
edema in a rat model of transient global brain ischemia-reperfusion. Artif. Cells,
Blood Substit. Immob. Biotechnol. 2002; 30: 25±42.
21. Yu BL, Chang TMS: In vitro and in vivo enzyme studies of polyHb±tyrosinase. J.
Biotechnol. Bioeng. 2004; 32: 311±320.
22. Yu BL, Chang TMS: In vitro and in vivo effects of polyHb±tyrosinase on murine
B16F10 melanoma. Melanoma Res. 2004; 14: 197±202.
23. Yu BL, Chang TMS: Effects of combined oral administration and intravenous
injection on maintaining decreased systemic tyrosine levels in rats. Artif. Cells Blood
Substit. Immobil. Biotechnol. 2004; 32: 127±147.
24. Rudolph AS, Rabinovici R, Feuerstein GZ (eds): Red Blood Cell Substitutes. New
York: Marcel Dekker, Inc., 1997.
25. Tsuchida E (ed.): Blood Substitutes: Present and Future Perspectives. Amsterdam:
Elsevier, 1998.
26. Philips WT, Klpper RW, Awasthi VD, Rudolph AS, Cliff R, Kwasiborski VV,
Goins, BA: Polyethylene glyco-modified liposome-encapsulated hemoglobin: a long
circulating red cell substitute. J. Pharm. Exp. Therapeutics 1999; 288: 665±670.
27. Yu WP, Chang TMS: Submicron biodegradable polymer membrane hemoglobin
nanocapsules as potential blood substitutes: a preliminary report. J. Artif. Cells,
Blood Substit. Immobiliz. Biotechnol. 1994; 22: 889±894.
28. Chang TMS and Yu WP: Nanoencapsulation of hemoglobin and red blood cell
enzymes based on nanotechnology and biodegradable polymer; in Blood Substitutes:
Principles, Methods, Products and Clinical Trials. Vol. 2 (Chang TMS, ed.) Karger:
Basel, 1998, pp. 216±231.
29. Chang TMS, Powanda D, Yu WP: Analysis of polyethylene±glycol±polylactide
nano-dimension artificial red blood cells in maintaining systemic hemoglobin levels
and prevention of methemoglobin formation. Artif. Cells, Blood Substit. Biotechnol.
2003; 31(3): 231±248.
Search WWH ::
Custom Search